Saturday, February 28, 2015 10:53:16 AM
The company has four products in its pipeline (seven if you include the various orphan indications for MANF) each of which could justify a market cap three to five times the current one.
It's only a matter of time before a singular catalyst will double the share price.
Stay tuned for news.
Twitter: @AmarantusBio
Gerald's comments:
"I'd be buying all day long here."
"2015 will be a monumental year for the company."
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM